Every number here traces to a published clinical trial. No estimates, no blending studies. Just what the data actually says.
The STEP 1 trial enrolled 1,961 people for 68 weeks. Average loss was 14.9% of body weight. Here is the full distribution, broken down by starting weight.
Read guide →Tirzepatide averaged 20.9% weight loss in SURMOUNT-1. Semaglutide 2.4mg averaged 14.9% in STEP 1. A straight read of both trials, including why you cannot compare them directly.
Read guide →List price, GoodRx, manufacturer savings cards, insurance, and telehealth. Every pricing path for Wegovy, Zepbound, Mounjaro, and Ozempic, with what changed after the FDA shortage ended.
Read guide →